Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q2 FY24 results · Jul–Sep 2023
Supriya Lifescience reported revenue from operations of ₹140.09 crore (up 24.9% from Q2 FY23) and net profit of ₹23.88 crore (up 41.6% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a standalone basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.09 | 112.17 | +24.9% | 132.02 | +6.1% |
| Other income | 2.47 | 2.60 | −5.3% | 2.92 | −15.5% |
| Total income | 142.56 | 114.78 | +24.2% | 134.94 | +5.6% |
| Profit before tax | 29.78 | 27.42 | +8.6% | 42.64 | −30.2% |
| Net profit for the period | 23.88 | 16.86 | +41.6% | 28.51 | −16.2% |
| EPS, basic (₹) | 2.97 | 2.10 | +41.4% | 3.54 | −16.1% |
| Net margin (%) | 17.0 | 15.0 | 21.6 |
Standalone
- Filed with BSE
- 22 Nov 2023, 12:53 IST
- Board meeting
- 07 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE